Abstract: Objective To observe the clinical outcome of polyene phosphatidyl choline capsules combing compound glycyrrhizin in the treatment of non-alcoholic fatty liver disease. Methods 60 patients with non-alcoholic fatty liver disease in No. 941 Hospital of PLA Logistic Support Troops from December 2017 to December 2021 were included in current studies. The patients were randomly divided into control group and observation group, and each group contained 30 patients. Patients in control group were treated with polyene phosphatidyl choline capsules while patients in observation group were administrated with polyene phosphatidyl choline capsules together with compound glycyrrhizin. The therapeutic outcome was observed herein. Results There were no remarkable alterations in the incidence of side effects during the treatment as well as aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) before the treatment (P>0.05). After treatment, compared to control group, the total effective rate and HDL-C in observation group were increased, while AST, ALT,TC, TG and LDL-C were decreased significantly (P<0.05). Conclusion Combination of polyene phosphatidyl choline capsules and compound glycyrrhizin in the treatment of non-alcoholic fatty liver disease could remarkable enhance the therapeutic outcome, improve liver function and blood lipids in patients, promote rehabilitation, and reduce side effects, which indicated the potential high safety.

Key words: non-alcoholic fatty liver disease, polyene phosphatidyl choline capsules, compound glycyrrhizin